Johnson & Johnson has sued a U.S. government agency over a closely watched dispute focusing on payment methods for some ...

Below is Validea's guru fundamental report for JOHNSON & JOHNSON (JNJ). Of the 22 guru strategies we follow, JNJ rates highest using our P/B Growth Investor model based on the published strategy ...

Johnson & Johnson announced that the U.S. Food and Drug Administration has granted nipocalimab Breakthrough Therapy designation for the ...

Johnson & Johnson's robust pharmaceutical division drives growth amidst competitive challenges. Strategic divestitures and acquisitions shape JNJ's market presence and future prospects.

Below is Validea's guru fundamental report for JOHNSON & JOHNSON (JNJ). Of the 22 guru strategies we follow, JNJ rates highest using our P/B Growth Investor model based on the published strategy ...

The U.S. Food & Drug Administration has approved Johnson & Johnson's device for a type of condition which causes abnormal ...

Johnson & Johnson's Tom Aelbrecht, N-VA's Jan Jambon, Flemish Minister for Welfare and Culture ... [+] Caroline Gennez, Deputy department head of the nursing department Siska Van den Bergh ...

Johnson & Johnson (J&J), formed in 1886, is a prominent American multinational corporation known for medical devices, pharmaceuticals, and consumer packaged goods.

A phase 3 study found that a subcutaneous version of Johnson & Johnson's Tremfya (guselkumab) was effective in treating Crohn's disease. Data from the GRAVITI study showed that the SC version of ...

Johnson & Johnson (JNJ) is scheduled to report earnings on January 22, 2025. The last reported earnings were for reported on October 15, 2024 for Q3.